Valeant: Is There Anything Else?-analyst opinionMizuho’s Irina Koffler discusses wonders if Valeant Pharmaceuticals International (VRX) will have to disclose anything else after ending its relationship with Philidor:
Koffler was right about Valeant not getting much benefit from Ackman’s call. In fact, you could say it was harmed, as shares have tumbled 11% to $98.78 at 12:05 p.m. today, near the low of the day. Horizon Pharma has slipped 5.7% to $16.50.
Koffler rates Valeant a Buy.
https://blogs.barrons.com/stockstowatchtoday/2015/10/30/valeant-is-there-anything-else/